Related Experiment Video
Updated: Apr 18, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Therapeutic outcomes of acute promyelocytic leukemia in children
Sirine Chatti1, Emna Azza1, Marwa Bahri1
1Hôpital Aziza Othmana Tunis, Tunis, Tunisia.
Insights
Pediatric acute promyelocytic leukemia (APL) outcomes were evaluated in 30 children. While remission rates were high, relapsed patients faced a poor prognosis, indicating a need for further research.
Area of Science:
- Pediatric Hematology
- Oncology
- Leukemia Research
Background:
- Acute promyelocytic leukemia (APL) is a distinct subtype of leukemia in children.
- APL in pediatric populations is underreported, necessitating focused research on its unique characteristics and outcomes.
Purpose of the Study:
- To report the therapeutic outcomes of APL in pediatric patients.
- To analyze treatment effectiveness and survival rates in children diagnosed with APL.
Main Methods:
- A descriptive, retrospective, single-center study was conducted.
- Data from 30 pediatric APL patients treated over 18 years at Aziza Othmana Hospital were analyzed.
Main Results:
- The median age at diagnosis was 11 years; 50% were high-risk.
- Post-induction remission was achieved in 86.6% of patients.
- The 5-year overall survival rate was 70.6%, with a relapse rate of 80%.
Conclusions:
- Therapeutic outcomes for pediatric APL were satisfactory but highlighted a poor prognosis for relapsed cases.
- Further investigation into the characteristics of APL relapse in children is warranted.
Introduction:
In children, acute promyelocytic leukemia is a distinct and underreported entity. The objective of our study is to report the therapeutic outcomes of APL in the pediatric population.
Methods:
This was a descriptive, retrospective, single-center study including 30 patients diagnosed with APL over an 18-year period. Patients were treated in the Hematology Department of Aziza Othmana Hospital in Tunis.
Results:
The median age at diagnosis was 11 years, with a sex ratio of 0.87. Half of the patients were classified as high-risk. Post-induction cytologic remission was achieved in 86.6 % of patients. There were five cases of relapse, 60 % of which were early relapses. The 5-year overall survival rate was 70.6 %.The 5-year event-free survival rate was 72 %. The 5-year relapse-free survival rate was 80 %.
Conclusion:
Although our results were satisfactory, they revealed a poor prognosis for relapsed patients. A larger study focusing on relapse characteristics is needed.
